John P. Sharp

2019 - PhaseBio Pharmaceuticals

In 2019, John P. Sharp earned a total compensation of $747.9K as Chief Financial Officer at PhaseBio Pharmaceuticals, a 61% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$182,325
Option Awards$199,350
Salary$356,283
Other$9,905
Total$747,863

Sharp received $356.3K in salary, accounting for 48% of the total pay in 2019.

Sharp also received $182.3K in non-equity incentive plan, $199.4K in option awards and $9.9K in other compensation.

Rankings

In 2019, John P. Sharp's compensation ranked 10,471st out of 13,971 executives tracked by ExecPay. In other words, Sharp earned more than 25.1% of executives.

ClassificationRankingPercentile
All
10,471
out of 13,971
25th
Division
Manufacturing
4,229
out of 5,695
26th
Major group
Chemicals And Allied Products
1,635
out of 2,194
26th
Industry group
Drugs
1,401
out of 1,880
26th
Industry
Pharmaceutical Preparations
1,038
out of 1,392
25th
Source: SEC filing on April 24, 2020.

Sharp's colleagues

We found two more compensation records of executives who worked with John P. Sharp at PhaseBio Pharmaceuticals in 2019.

2019

Jonathan Mow

PhaseBio Pharmaceuticals

Chief Executive Officer

2019

John Lee

PhaseBio Pharmaceuticals

Chief Medical Officer

News

You may also like